Clinical Trials Logo

Clinical Trial Summary

Background Anal fissure is one of the most common anorectal problems. After an outbreak of coronavirus disease (COVID-19) has rapidly spread from China to almost all over the world, it nearly affected all countries. In spite of its typical presentation in the form of fever, cough, myalgia, fatigue and pneumonia, other GIT manifestations were reported. We found some of COVID-19 survivors who had complained from anal fissure problem. The aim of this study was to report the prevalence of acute anal fissure among COVID-19 patients, its possible risk factors and outcome. Methods This is a retrospective cross-sectional study which was conducted over three months from the start of September 2020 to the end of November 2020 at Mansoura university isolation hospital, on COVID-19 patients' who were diagnosed with anal fissure. Those who survived and were discharged home safely were telephone called to pick up whether they suffered from any symptoms of anal pain, difficulty in defecation suggesting anal fissure, in order to identify their outcomes, the risk factors for anal fissure development and how they were managed. Results A total of 176 patients were enrolled in this study. Patients were categorized into two groups. The first group included patients who developed anal fissure (n=65) and the 2nd group included patients who did not develop anal fissure (n=111). No significant difference was noted in demographic data apart from the age which was younger in the fissure group. The incidence of anal fissure was 36.9% of total population. The majority of patients' anal fissure problem resolved spontaneously after patients improved from the COVID symptoms without receiving any treatment (43.1%). Conclusion Anal fissure is quite common problem after COVID-19. Young and middle age patients are more vulnerable to develop anal fissure after COVID-19 infection.


Clinical Trial Description

Methods Study design This is a retrospective cross-sectional study which was conducted over three months from the start of September 2020 to the end of November 2020 at Mansoura university isolation hospital, on COVID-19 patients' who were diagnosed to have anal fissure. Mansoura isolation hospital is a tertiary referral center that admits COVID -19 patients. Patient who had experienced any symptoms that suggests COVID-19 infection and their nasal swab tested PCR positive were admitted. Also patients with CT chest findings that suggest COVID-19 infection were admitted. The study protocol was approved by the Institutional Review Board (IRB) of Mansoura University (IRB No. R.21.07.1383). Informed consents were obtained from the patients. Eligibility criteria Patients of both genders aging between 20-70 years with or without associated co-morbidities who received treatment for COVID-19 infection, were discharged home safely, and presented with anal fissure during the follow up were included. Patients who didn't experience anal pain or anal fissure, and patients who died were excluded from this study. Patient interview By checking the Electronic medical records (EMR) during those 3 months, all patients' data was addressed and those who survived and were discharged home safely were telephone called to pick up whether they suffered from any symptoms of anal pain, difficulty in defecation suggesting anal fissure. Trying to identify their outcomes, the risk factors for anal fissure development and how they were managed. We telephoned about 350 patients, 176 replied to us while 174 didn't answer. Those who suffered from anal pain problems were advised to come to our colorectal outpatient clinic (OPC) to be examined to make sure of the diagnosis. But, because of the pandemic situation, no patient came to the OPC. Further telephone calls were conducted to those who were diagnosed with anal fissure to ask about their outcomes, to pick up how many of them were managed medically or their symptoms resolved spontaneously or needed surgical interference. All patient recorded data including; age, sex, the associated co-morbidities, and the degree of severity of infection, respiratory or GIT symptoms and the need for oxygen therapy were collected. Other symptoms as fever, loss of smell and/or taste sensation, constipation or diarrhea and also the duration of these symptoms were checked. Additionally, the investigations that were conducted either laboratory or radiological. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05736926
Study type Observational
Source Mansoura University
Contact
Status Completed
Phase
Start date September 1, 2020
Completion date November 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04578210 - Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia Phase 1/Phase 2
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Completed NCT04720794 - A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Completed NCT04598620 - Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate
Completed NCT05517941 - Effect of Active Cycle Breathing Technique Along With Incentive Spirometer on COVID19 Patient N/A
Recruiting NCT04480333 - Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 Phase 1
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Active, not recruiting NCT04558476 - Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation Phase 2
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT05639998 - BBV152/BBV154 Heterologus Prime-Boost Study Phase 2
Completed NCT04523246 - Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents Early Phase 1
Withdrawn NCT04386447 - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Phase 2
Recruiting NCT04583566 - Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04579588 - Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Terminated NCT03331445 - Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections Phase 2
Recruiting NCT04573348 - T Cells Response to SARS COV 2 Peptides
Completed NCT04615936 - Nasal Photodisinfection COVID-19 Proof of Concept Study N/A